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INTRODUCTION
Antenatal intracranial hemorrhage is a rare cause of intrauter-
ine fetal death, with the incidence of 4.6-5.1% in autopsy
study of stillborn fetuses (1, 2). Sherer et al. performed a lit-
erature survey on predisposing factors of antenatal intracranial
hemorrhage from 1966 to 1998, and maternal factors includ-
ed hematologic disorders (alloimmune and idiopathic throm-
bocytopenia, and von Willebrand’ s disease), seizures, abdom-
inal trauma, cholestasis of pregnancy, drug abuse, and specif-
ic medication including warfarin (3).
Warfarin-associated fetal bleeding event is a rare problem,
with the incidence of 4.3% in the literature review by Hall
et al. (4). Some authors reported fetal intracranial hemorrhages
confirmed by prenatal ultrasound (Table 1) (5, 6).
The present case is a rare example of warfarin-associated fetal
intracranial hemorrhage which stresses the importance of war-
farin as a cause of fetal intracranial bleeding.
CASE REPORT
A 27-yr-old woman had been taking warfarin (7.5 mg per
day) for 10 yr since mitral valve replacement and obliteration
of patent ductus arteriosus in 1991. She was found to be preg-
nant at five weeks of gestation. She received heparinization
instead of warfarin medication by subcutaneous nadroparin
(one of low-molecular-weight heparin) 3,800 IU/mL twice a
day for nine weeks, and then took oral anticoagulant again,
7 mg per day. Prothrombin time by international normalized
ratio (INR) was maintained between 2.3 and 3.0.
At 24 weeks of gestation, fetal ultrasound revealed echogenic
subdural mass in the left cerebral hemisphere associated with
mild ventricular enlargement (Fig. 1A). In addition, there was
an arachnoid cyst in the posterior cranial fossa along with cere-
bellar atrophy. On MRI, this intracranial mass showed mixed
low and high signal intensity, suggesting active bleeding (Fig.
1B). Maternal TORCH test was negative and fetal karyotype
was 46,XX. The fetus was delivered by labor induction one
week later, and died three hours after delivery.
At autopsy, the fetal body weight was 800 g, and the mea-
surements including head circumference of 24.5 cm were ap-
propriate for those of 25 weeks of gestation. There was no con-
genital anomaly. Cerebrospinal fluid was bloody, and the left
cerebral hemisphere showed a subdural hematoma over the left
Sylvian fissure with compression of underlying brain parenchy-
ma (Fig. 2). No other significant findings were seen in brain
and spinal cord. The thoracic and abdominal visceral organs
were generally pale, but revealed no hemorrhagic foci. The liver,
spleen, adrenal glands, and kidney showed exaggerated ex-
tramedullary hematopoiesis.
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Warfarin-associated Fetal Intracranial Hemorrhage
: A Case Report
A 27-yr-old woman who had been taking warfarin for 10 yr after mitral valve replace-
ment became pregnant. After knowing her pregnancy, she received heparinization
for nine weeks instead of warfarin, and took oral anticoagulant again. At 24 weeks
of gestation, fetal ultrasound and MRI showed a left subdural hematoma, and the
pregnancy was terminated. Subdural hematoma was demonstrated on autopsy. Fatal
bleeding of the fetus is a rare complication of maternal warfarin medication, occur-
ring mostly in the second or third trimester. There is no alternative regimen available,
so that regular monitoring by fetal ultrasound and strict control of warfarin dose with
regular measurement of prothrombin time are the best way to prevent intrauterine
fetal death due to bleeding.
Key Words : Fetus; Heart Valve Diseases; Intracranial Hemorrhages; Pregnancy; Warfarin
Received : 23 September 2002
Accepted : 17 October 2002Warfarin-associated Fetal Intracranial Hemorrhage 765
DISCUSSION
Warfarin is used for the prevention of systemic thromboem-
bolism in patients having prosthetic heart valves or atrial fib-
rillation, of myocardial infarction or stroke, and for the treat-
ment of deep vein thrombosis (7). Unfortunately, warfarin is
known to have some teratogenic effects. Warfarin embryo-
pathy, characterized by nasal hypoplasia and/or stippled epi-
physes, is associated with the exposure to warfarin in the first
trimester (4). It is thought to be related to inhibition of post-
transitional carboxylation of vitamin K-dependent calcium-
binding proteins, including osteocalcin and some bone matrix
proteins (8). Central nervous system anomaly, i.e., agenesis
of corpus callosum, Dandy-Walker syndrome, and midline
cerebellar atrophy, and optic nerve atrophy are associated with
the warfarin exposure in the second or the third trimester (4).
Pathogenesis of these brain anomalies are not yet evaluated.
In fetal bleeding event, like central nervous system anoma-
ly, warfarin exposure during the second or the third trimester
was noted in most of these cases (4). It has also been proven
that warfarin can induce fetal hemorrhage by experimental
study. Howe and Webster demonstrated that an excessive
dose of warfarin could induce fetal intracranial hemorrhage
in spite of vitamin K injection (9).
Robbins et al. (5)
Ville et al. (6)
Case 1 Case 2
Present case
Maternal disease VHD* with prosthetic valve Pulmonary embolism VHD*(aortic, mitral) VHD* (mitral) with
prosthetic valve
Warfarin exposure in  1st week - 26th week - 15th week - 1st-5th week
pregnancy 14th-23th week
Warfarin dose (mg) NA
� 6 to 3
� 5-6 6-7
Prothrombin time (INR
�)N A
� 8.6 to 1.7-2.5
� 0.7-1.9 2.2-3.0
Gestational age at 32 32 29 23
diagnosis (weeks)
Hemorrhage site Subdural, bilateral Intraventricular Intraventricular Subdural, left
Fetal outcome Spontaneous delivery  Stillborn at 36 weeks Stillborn at 29 weeks Delivery by labor
at 34 weeks, died induction at 25 weeks,
3 hr later died 3 hr later
*VHD: Valvular heart disease; 
� NA: Not available; 
� : On the 10th day of warfarin with the dose of 6 mg per day, INR was elevated to 8.6. When the dose
was decreased to 3 mg, the INR level was maintained between 1.7 and 2.5; 
�INR: International normalized ratio.
Table 1. Cases of warfarin-associated fetal hemorrhage confirmed by imaging study
Fig. 1. Prenatal imaging study of fetus. (A) There is an echogenic mass at the subdural area of left temporoparietal area on ultrasonogra-
phy. (B) In T2-weighted MRI image, the mass shows mixed low and high signal intensity, suggesting an active bleeding. The brain at this
site is compressed, and the left lateral ventricle is slightly larger than the right.
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The fetal subdural hemorrhage in our case is most likely
due to the maternal warfarin exposure based on the follow-
ing assumptions; (a) warfarin can cross the placental barrier to
reach the fetal blood circulation, (b) the exposure was occurred
during the second trimester, and (c) no hemorrhagic foci were
found until the beginning of the second oral anticoagulant
therapy.
A question to be addressed is why the brain is the most fre-
quent site of fetal hemorrhage. Although some of the report-
ed cases had hemorrhage other than the brain (10, 11), majori-
ty of the cases had intracranial hemorrhage only. The patho-
genesis is still unknown, but it may be different from that of
neonatal intraventricular or periventricular hemorrhage in
prematurity, which is suggested to be associated with the frag-
ile germinal matrix of the brain (12). In warfarin-associated
fetal intracranial hemorrhage, intraventricular or periventric-
ular area is not so frequent bleeding region and prematurity
is not a risk factor.
Warfarin-induced fetal intracranial hemorrhage is a fatal
condition. Including our case, most were stillborn or died with-
in one day after delivery. A baby with intraventricular hem-
orrhage was managed with shunt insertion and actually alive,
but the baby showed subsequent mental retardation and blind-
ness (13). Therefore, prevention is very important.
As for the best management of pregnant women with pros-
thetic heart valves to prevent fetal hemorrhage, discontinua-
tion of warfarin and use of only heparin throughout the preg-
nancy seems ideal, because it is well known that heparin can-
not cross the placental barrier. Indeed, no case has been report-
ed on fetal hemorrhage with maternal heparin injection. How-
ever, the mothers treated with heparin were more prone to
spontaneous abortion or stillborn fetuses than control group
(4, 14). In addition, some studies revealed that unfractionat-
ed heparin was more dangerous than warfarin for the mother
with mechanical heart valves (14). Low-molecular-weight hep-
arin can be the alternative regimen for those mothers, but no
randomized studies about full-time use of low-molecular-
weight heparin have yet been available. It is only used during
the first trimester and some weeks before delivery, in which
warfarin is contraindicated.
Second, reduction of warfarin dose may be considered. Ac-
cording to Table 1, however, prothrombin time levels by INR
are 3.0 or less, as suggested by Hirsh et al. (7). Therefore, these
hemorrhages may not be associated with excessive dose of war-
farin. And if the dose is reduced, maternal complication may
increase. So, reduction of warfarin dose will not be helpful.
Vitamin K can be used as additional treatment. However,
its effectiveness is doubtful, because vitamin K cannot cross
the placental barrier freely. In one case, fetal coagulation factors
II, VII, X, and XII were severely decreased in spite of mater-
nal vitamin K injection (6). In maternal and fetal blood tests,
the average neonatal vitamin K level was less than one tenth
of the average maternal level, and the differences are wider
after vitamin K injection to their mother before the delivery
(15). And it is well documented that vitamin K can induce
anaphylactoid reaction (16). So, its administration should be
carefully considered.
In conclusion, warfarin-associated fetal hemorrhage is a fatal
event. Unfortunately, there is no alternative regimen that can
replace warfarin for pregnant women with mechanical heart
valves yet. Regular monitoring of fetal ultrasound study and
strict control of warfarin dose with regular measurement of
prothrombin time are the best way to prevent intrauterine
fetal death due to bleeding, although there is no direct way to
prevent fetal intracranial hemorrhage so far.
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